A PYMNTS Company

Canada: Valeant aims high with 2014 merger spree plans

By  |  January 30, 2014

Valeant Pharmaceuticals has major plans for 2014, including the goal of becoming one of the world’s five-largest pharmaceutical companies. That goal, reports say, includes reaching a market value of more than $150 billion.

Valeant, based in Canada, has upped its market value from less than $3 billion in 2010 to its current value of $44 billion through major acquisitions.

Now, plans to merge with Actavis could now add yet another boost to its market value this year. Industry experts also note that a deal with Teva Pharmaceuticals could push Valeant in the right direction.

According to the head of healthcare research at Aegis Capital, Valeant’s $150 billion goal “is actually not unrealistic at all.”

”This transaction is going to happen in 2014, and it’s going to be a biggie,” he said.

Full Content: Businessweek

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.